TY - JOUR AU - Hammer, S. M. AU - Eron, J. J. AU - Reiss, P. AU - Schooley, R. T. AU - Thompson, M. A. AU - Walmsley, S. PY - 2008 DA - 2008// TI - Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JO - JAMA VL - 300 UR - https://doi.org/10.1001/jama.300.5.555 DO - 10.1001/jama.300.5.555 ID - Hammer2008 ER - TY - JOUR AU - Palella, F. J. AU - Delaney, K. M. AU - Moorman, A. C. AU - Loveless, M. O. AU - Fuhrer, J. AU - Satten, G. A. PY - 1998 DA - 1998// TI - Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection JO - N Engl J Med VL - 338 UR - https://doi.org/10.1056/NEJM199803263381301 DO - 10.1056/NEJM199803263381301 ID - Palella1998 ER - TY - JOUR AU - Arribas, J. R. AU - Pozniak, A. L. AU - Gallant, J. E. AU - DeJesus, E. AU - Gazzard, B. AU - Campo, R. E. PY - 2008 DA - 2008// TI - Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis JO - J Acquir Immune Defic Syndr VL - 47 UR - https://doi.org/10.1097/QAI.0b013e31815acab8 DO - 10.1097/QAI.0b013e31815acab8 ID - Arribas2008 ER - TY - JOUR AU - Gupta, R. AU - Hill, A. AU - Sawyer, A. W. AU - Pillay, D. PY - 2008 DA - 2008// TI - Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials JO - Clin Infect Dis VL - 47 UR - https://doi.org/10.1086/590943 DO - 10.1086/590943 ID - Gupta2008 ER - TY - CHAP AU - Hirsch, M. S. AU - Gunthard, H. F. AU - Schapiro, J. M. AU - Brun-Vezinet, F. AU - Clotet, B. AU - Hammer, S. M. PY - 2008 DA - 2008// TI - Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA BT - Clin Infect Dis ID - Hirsch2008 ER - TY - JOUR AU - Lazzarin, A. AU - Clotet, B. AU - Cooper, D. AU - Reynes, J. AU - Arasteh, K. AU - Nelson, M. PY - 2003 DA - 2003// TI - Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia JO - N Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa035211 DO - 10.1056/NEJMoa035211 ID - Lazzarin2003 ER - TY - JOUR AU - Temesgen, Z. AU - Feinberg, J. PY - 2007 DA - 2007// TI - Tipranavir: a new option for the treatment of drug-resistant HIV infection JO - Clin Infect Dis VL - 45 UR - https://doi.org/10.1086/520847 DO - 10.1086/520847 ID - Temesgen2007 ER - TY - JOUR AU - Hicks, C. B. AU - Cahn, P. AU - Cooper, D. A. AU - Walmsley, S. L. AU - Katlama, C. AU - Clotet, B. PY - 2006 DA - 2006// TI - Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials JO - Lancet VL - 368 UR - https://doi.org/10.1016/S0140-6736(06)69154-X DO - 10.1016/S0140-6736(06)69154-X ID - Hicks2006 ER - TY - JOUR AU - Clotet, B. AU - Bellos, N. AU - Molina, J. M. AU - Cooper, D. AU - Goffard, J. C. AU - Lazzarin, A. PY - 2007 DA - 2007// TI - Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials JO - Lancet VL - 369 UR - https://doi.org/10.1016/S0140-6736(07)60497-8 DO - 10.1016/S0140-6736(07)60497-8 ID - Clotet2007 ER - TY - JOUR AU - Lazzarin, A. AU - Campbell, T. AU - Clotet, B. AU - Johnson, M. AU - Katlama, C. AU - Moll, A. PY - 2007 DA - 2007// TI - Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, doubleblind, placebo-controlled trial JO - Lancet VL - 370 UR - https://doi.org/10.1016/S0140-6736(07)61048-4 DO - 10.1016/S0140-6736(07)61048-4 ID - Lazzarin2007 ER - TY - JOUR AU - Madruga, J. V. AU - Cahn, P. AU - Grinsztejn, B. AU - Haubrich, R. AU - Lalezari, J. AU - Mills, A. PY - 2007 DA - 2007// TI - Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial JO - Lancet VL - 370 UR - https://doi.org/10.1016/S0140-6736(07)61047-2 DO - 10.1016/S0140-6736(07)61047-2 ID - Madruga2007 ER - TY - CHAP AU - Cohen, C. J. AU - Berger, D. S. AU - Blick, G. AU - Grossman, H. A. AU - Jayaweera, D. T. AU - Shalit, P. PY - 2008 DA - 2008// TI - Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial BT - AIDS ID - Cohen2008 ER - TY - CHAP AU - Haubrich, R. AU - Cahn, P. AU - Grinsztein, B. AU - Lalezari, J. AU - Madruga, J. AU - Mills, A. PY - 2008 DA - 2008// TI - DUET-1: week-48 results of a phase III randomized double-blind trial to evaluate the efficacy and safety of TMC125 vs placebo in 612 treatment-experienced HIV-1-infected patients BT - 15th Conference on Retroviruses and Opportunistic Infections ID - Haubrich2008 ER - TY - JOUR AU - Steigbigel, R. T. AU - Cooper, D. A. AU - Kumar, P. N. AU - Eron, J. E. AU - Schechter, M. AU - Markowitz, M. PY - 2008 DA - 2008// TI - Raltegravir with optimized background therapy for resistant HIV-1 infection JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708975 DO - 10.1056/NEJMoa0708975 ID - Steigbigel2008 ER - TY - JOUR AU - Cooper, D. A. AU - Steigbigel, R. T. AU - Gatell, J. M. AU - Rockstroh, J. K. AU - Katlama, C. AU - Yeni, P. PY - 2008 DA - 2008// TI - Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708978 DO - 10.1056/NEJMoa0708978 ID - Cooper2008 ER - TY - CHAP AU - Roquebert, B. AU - Damond, F. AU - Collin, G. AU - Matheron, S. AU - Peytavin, G. AU - Benard, A. PY - 2008 DA - 2008// TI - HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro BT - J Antimicrob Chemother ID - Roquebert2008 ER - TY - JOUR AU - Gulick, R. M. AU - Lalezari, J. AU - Goodrich, J. AU - Clumeck, N. AU - DeJesus, E. AU - HORBAN, A. PY - 2008 DA - 2008// TI - Maraviroc for previously treated patients with R5 HIV-1 infection JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0803152 DO - 10.1056/NEJMoa0803152 ID - Gulick2008 ER - TY - JOUR AU - Hammer, S. M. AU - Eron, J. J. AU - Reiss, P. AU - Schooley, R. T. AU - THOMPSON, M. A. AU - Walmsley, S. PY - 2008 DA - 2008// TI - Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel JO - JAMA VL - 300 UR - https://doi.org/10.1001/jama.300.5.555 DO - 10.1001/jama.300.5.555 ID - Hammer2008 ER - TY - JOUR AU - Saag, M. AU - Goodrich, J. AU - Fatkenheuer, G. AU - Clotet, B. AU - Clumeck, N. AU - Sullivan, J. PY - 2009 DA - 2009// TI - A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1 JO - J Infect Dis VL - 199 UR - https://doi.org/10.1086/598965 DO - 10.1086/598965 ID - Saag2009 ER - TY - JOUR AU - Steigbigel, R. T. AU - Cooper, D. A. AU - Kumar, P. N. AU - Eron, J. E. AU - Schechter, M. AU - Markowitz, M. PY - 2008 DA - 2008// TI - Raltegravir with optimized background therapy for resistant HIV-1 infection JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708975 DO - 10.1056/NEJMoa0708975 ID - Steigbigel2008 ER - TY - CHAP AU - Hicks, C. AU - Gulick, R. M. PY - 2009 DA - 2009// TI - Raltegravir: The First HIV Type 1 Integrase Inhibitor BT - Clin Infect Dis ID - Hicks2009 ER - TY - CHAP AU - Iwamoto, M. AU - Hanley, W. D. AU - Petry, A. S. AU - Friedman, E. J. AU - Kost, J. T. AU - Breidinger, S. A. PY - 2009 DA - 2009// TI - Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics BT - Antimicrob Agents Chemother ID - Iwamoto2009 ER - TY - CHAP AU - Wenning, L. A. AU - Hanley, W. D. AU - Brainard, D. M. AU - Petry, A. S. AU - Ghosh, K. AU - Jin, B. PY - 2009 DA - 2009// TI - Effect of Rifampin, a Potent Inducer of Drug Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir BT - Antimicrob Agents Chemother ID - Wenning2009 ER - TY - JOUR AU - Grinsztejn, B. AU - Nguyen, B. Y. AU - Katlama, C. AU - Gatell, J. M. AU - Lazzarin, A. AU - Vittecoq, D. PY - 2007 DA - 2007// TI - Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial JO - Lancet VL - 369 UR - https://doi.org/10.1016/S0140-6736(07)60597-2 DO - 10.1016/S0140-6736(07)60597-2 ID - Grinsztejn2007 ER - TY - CHAP AU - Gatell, J. M. AU - Katlama, C. AU - Grinsztejn, B. AU - Eron, J. J. AU - Lazzarin, A. AU - Vittecoq, D. PY - 2009 DA - 2009// TI - Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in patients with limited treatment options in a phase II study BT - J Acquir Immune Defic Syndr ID - Gatell2009 ER - TY - JOUR AU - Grinsztejn, B. AU - Nguyen, B. Y. AU - Katlama, C. AU - Gatell, J. M. AU - Lazzarin, A. AU - Vittecoq, D. PY - 2007 DA - 2007// TI - Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial JO - Lancet VL - 369 UR - https://doi.org/10.1016/S0140-6736(07)60597-2 DO - 10.1016/S0140-6736(07)60597-2 ID - Grinsztejn2007 ER - TY - JOUR AU - Steigbigel, R. T. AU - Cooper, D. A. AU - Kumar, P. N. AU - Eron, J. E. AU - Schechter, M. AU - Markowitz, M. PY - 2008 DA - 2008// TI - Raltegravir with optimized background therapy for resistant HIV-1 infection JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708975 DO - 10.1056/NEJMoa0708975 ID - Steigbigel2008 ER - TY - JOUR AU - Cooper, D. A. AU - Steigbigel, R. T. AU - Gatell, J. M. AU - Rockstroh, J. K. AU - Katlama, C. AU - Yeni, P. PY - 2008 DA - 2008// TI - Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708978 DO - 10.1056/NEJMoa0708978 ID - Cooper2008 ER - TY - CHAP AU - Steigbigel, R. AU - Cooper, D. A. AU - Teppler, H. AU - Eron, J. J. AU - Gatell, J. M. AU - Kumar, P. N. PY - 2009 DA - 2009// TI - Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 phase III trials BT - Clin Infect Dis ID - Steigbigel2009 ER - TY - CHAP AU - Fagard, C. AU - Descamps, D. AU - Dubar, V. AU - Colin, C. AU - Taburet, A. M. AU - Roquebert, B. PY - 2009 DA - 2009// TI - Efficacy and safety of raltegravir plus etravirine and darunavir/ritonavir in treatment experienced patients with multidrug resistant virus: 48 weeks results from the ARNS 139 TRIO trial. 5th IAS BT - Cape Town ID - Fagard2009 ER - TY - CHAP AU - Imaz, A. AU - Del Saz, S. V. AU - Ribas, M. A. AU - Curran, A. AU - Caballero, E. AU - Falco, V. PY - 2009 DA - 2009// TI - Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection BT - J Acquir Immune Defic Syndr ID - Imaz2009 ER - TY - JOUR AU - Harris, M. AU - Larsen, G. AU - Montaner, J. S. PY - 2008 DA - 2008// TI - Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen JO - AIDS VL - 22 UR - https://doi.org/10.1097/QAD.0b013e328302f3b5 DO - 10.1097/QAD.0b013e328302f3b5 ID - Harris2008 ER - TY - JOUR AU - Towner, W. AU - Klein, D. AU - Kerrigan, H. L. AU - Follansbee, S. AU - Yu, K. AU - Horberg, M. PY - 2009 DA - 2009// TI - Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study JO - J Acquir Immune Defic Syndr VL - 51 UR - https://doi.org/10.1097/QAI.0b013e3181ae35de DO - 10.1097/QAI.0b013e3181ae35de ID - Towner2009 ER - TY - CHAP AU - Eron, J. AU - Andrade, J. M. J. AU - Zajdenverg, R. AU - Workman, J. AU - Cooper, D. AU - Young, B. PY - 2009 DA - 2009// TI - Switching from stable lopinavir/ritonavir based to raltegravir based combination antiretroviral therapy resulted in superior lipid profile at week 12 but did not demonstrate non-inferior efficacy at week 24. 16th Conference on Retrovirus Opportunistic Infections BT - Montreal ID - Eron2009 ER - TY - JOUR AU - Dinoso, J. B. AU - Kim, S. Y. AU - Wiegand, A. M. AU - Palmer, S. E. AU - Gange, S. J. AU - Cranmer, L. PY - 2009 DA - 2009// TI - Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy JO - Proc Natl Acad Sci USA VL - 106 UR - https://doi.org/10.1073/pnas.0903107106 DO - 10.1073/pnas.0903107106 ID - Dinoso2009 ER - TY - CHAP AU - Dinoso, J. B. AU - Jones, J. AU - McMahon, D. PY - 2009 DA - 2009// TI - Antiretroviral intensification does not reduce persistent HIV viremia on therapy. XIII International Drug Resistance Workshop BT - Fort Myers, Florida ID - Dinoso2009 ER - TY - JOUR AU - Bailey, J. R. AU - Sedaghat, A. R. AU - Kieffer, T. AU - Brennan, T. AU - Lee, P. K. AU - Wind-Rotolo, M. PY - 2006 DA - 2006// TI - Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells JO - J Virol VL - 80 UR - https://doi.org/10.1128/JVI.00591-06 DO - 10.1128/JVI.00591-06 ID - Bailey2006 ER - TY - JOUR AU - Cooper, D. A. AU - Steigbigel, R. T. AU - Gatell, J. M. AU - Rockstroh, J. K. AU - Katlama, C. AU - Yeni, P. PY - 2008 DA - 2008// TI - Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection JO - N Engl J Med VL - 359 UR - https://doi.org/10.1056/NEJMoa0708978 DO - 10.1056/NEJMoa0708978 ID - Cooper2008 ER -